Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MD1003 in Adrenomyeloneuropathy
NCT02961803Phase 3Completed
- Sponsor
- MedDay Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Jun 2016
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
A Phase 3 trial of biotin in adrenomyeloneuropathy (AMN), sponsored by MedDay Pharmaceuticals. Started Oct 2014; status: completed.
02
Drugs
biotin
03
Conditions
adrenomyeloneuropathy (AMN)
Beyond the preview
Go deeper on NCT02961803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961803.